Toxicological evaluation and antitumoral effect of hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma treatment.

Center of Molecular Immunology (CIM)0 个研究点目标入组 15 人开始时间: 2010年12月29日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Other. Purpose: Treatment

•1) Patients with CHC diagnosed, eligible for chemo-embolization. 2) Capacity to understand the study and readiness to sign the informed consent document. 3) Patients with measurable lesions (in, at least, one dimension: greater diameter) using conventional techniques (CAT and US). 4) Age >= 18 years and under 75 years. 5) ECOG general health condition <= 2 (Karnofsky >= 60%,). 6) Mean life expectancy over 2 months. 7) Child- Pugh-Turcotte A or B functional stage. 8) OKUDA I or II staging system. 9) Patients with organs and bone marrow working well, in line with the following parameters: leukocytes: >= 2,000 x 109/l, hemoglobine: >= 9 g/dl, absolute neutrophil counting: >= 1,500/ul, platelet counting: >=50,000/ul, creatinine clearing: >= 60 mL/min/1.73m2 (For patients with creatinine values higher than normal, as established by the institution). Electrocardiogram: without alterations in auricularventricular conduction. 10) Female reproductive-age patients should be pregnancy-tested negative and use appropriate contraceptives such as IU devices, hormonal contraceptives, barrier methods or tubal ligation. Men should use contraceptives while on treatment. 11) Patients who have been successfully treated against skin carcinomas or in situ uterus carcinoma.

•1) Terminally ill patients with life expectancy shorter than 1 month. 2) Cirrhotic patients in functional stage C according to Child-Pugh-Turcotte Classification. 3) Patients on other research product. 4) Patients with allergy history attributed to chemical or biological compounds similar to TheraCIM hR3 MAb or the chemotherapy used in the trial. 5) Patients with uncontrolled intercurrent diseases, including active infections, symptomatic congestive heart failure, unstable angina pectoris, and mental or social diseases limiting adherence to clinical trial requirements. 6 As a result of potential and unknown adverse events in infants, breastfeeding women will not be included in the clinical trial. 7) Patients with previous malignant neoplasias, except those patients who have been on appropriate treatment for skin carcinomas or in situ uterus carcinomas. 8) Patients with extrahepatic metastasis. 9) Patients with hepatic encephalopathy. 10) Patients with biliary obstruction. 11) Patients with hepatofugal portal flow. 12) Tumor size exceeding liver size by 50 percent. 13) Patients with serum bilirubin over 40umol/l. 14) Patients with TGP over 100 UI/l.

发起方

Center of Molecular Immunology (CIM)